US Insurer Spending on Ivermectin Prescriptions for COVID-19

JAMA. 2022 Feb 8;327(6):584-587. doi: 10.1001/jama.2021.24352.

Abstract

This study examines insurer coverage of ivermectin prescriptions for COVID-19 in the US.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiparasitic Agents / economics*
  • Antiparasitic Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • Cross-Sectional Studies
  • Female
  • Health Expenditures / statistics & numerical data*
  • Humans
  • Insurance Carriers / economics*
  • Insurance, Health / economics
  • Ivermectin / economics*
  • Ivermectin / therapeutic use
  • Male
  • Medicare / economics
  • Middle Aged
  • Off-Label Use / economics*
  • United States
  • Young Adult

Substances

  • Antiparasitic Agents
  • Ivermectin